SB1998 amends the Illinois Antitrust Act to create a state-level review and notice process for certain health care mergers, acquisitions, and contracting affiliations. The bill defines a broad set of “covered transactions” involving health care facilities and provider organizations, including hospitals, ambulatory surgical treatment centers, kidney disease treatment centers, certain outpatient surgical sites, and provider organizations that negotiate with insurers or third-party administrators. It also defines private equity groups and hedge funds for purposes of the bill, and it specifically requires Attorney General consent before a covered transaction may take effect if such an entity provides any financing to the deal.
Under the bill, parties to a covered transaction must give the Attorney General notice at least 30 days before closing or the effective date. For transactions already subject to federal Hart-Scott-Rodino filing, submitting that filing to the Attorney General satisfies the notice requirement; for certain facility ownership changes, filing with the Health Facilities and Services Review Board also satisfies notice. For other transactions, the bill requires basic identifying and descriptive information about the parties and the deal. The Attorney General may request additional information within 30 days, and the transaction is delayed until 30 days after substantial compliance with that request. The bill also authorizes civil penalties of up to $500 per day for noncompliance and allows the Attorney General to seek injunctive relief in Sangamon or Cook County.
The bill’s practical impact would be to expand state oversight of health care consolidation and private investment in Illinois health care, giving the Attorney General a stronger role in reviewing transactions that could affect competition, pricing, or access to care. It would affect hospitals, surgical centers, dialysis facilities, provider networks, accountable care organizations, and out-of-state entities doing business with Illinois patients, especially where private equity or hedge fund financing is involved. It would also interact with existing Illinois health facility licensing and planning laws, as well as federal antitrust review processes.
The available context does not include committee transcripts or recorded votes, so there is no documented legislative debate or roll-call sentiment to summarize. Based on the bill’s structure and caption, the measure appears aimed at curbing potentially harmful health care consolidation and increasing transparency around ownership changes. The inclusion of private equity and hedge fund financing suggests a policy concern about financial investors influencing health care transactions, and that issue is likely to be a central point of discussion if the bill advances.
The main points of contention are likely to be the scope of the Attorney General’s authority, the breadth of the definitions of covered transactions and health care facilities, and the special consent requirement for transactions financed by private equity groups or hedge funds. Supporters would likely view the bill as a consumer-protection and antitrust measure, while opponents may argue it could slow legitimate transactions, add regulatory burden, and discourage investment in health care providers.
The bill would amend Section 7.2a of the Illinois Antitrust Act to add a mandatory notice-and-review framework for health care consolidation transactions and to require Attorney General consent when private equity or hedge fund financing is involved. It would create new disclosure obligations, delay closing timelines in some cases, authorize penalties and injunctions for noncompliance, and operate alongside federal HSR review and the Illinois Health Facilities Planning Act.
No committee transcript or vote history is provided, so there is no direct record of legislative sentiment. The bill’s caption and provisions suggest a generally reform-oriented, oversight-focused approach to health care consolidation, with an apparent policy preference for stronger scrutiny of mergers and investor-backed transactions. The likely overall tone is supportive among proponents of antitrust enforcement and skeptical among stakeholders concerned about regulatory delay and investment barriers.
The most notable likely contention is over the bill’s requirement that the Attorney General must consent to any covered transaction financed by a private equity group or hedge fund, which is more restrictive than a simple notice regime. Another likely dispute is the breadth of the bill’s definitions, including which facilities and provider organizations are covered and how out-of-state entities are treated if they generate significant revenue from Illinois patients. Health care systems, provider groups, and investors may view the bill as burdensome or uncertain, while consumer advocates, antitrust proponents, and regulators may support it as necessary to preserve competition and oversight.